218 related articles for article (PubMed ID: 15978877)
21. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
22. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
23. Recent patents of dipeptidyl peptidase IV inhibitors.
Mendieta L; Tarrago T; Giralt E
Expert Opin Ther Pat; 2011 Nov; 21(11):1693-741. PubMed ID: 22017411
[TBL] [Abstract][Full Text] [Related]
24. 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
Tsu H; Chen X; Chen CT; Lee SJ; Chang CN; Kao KH; Coumar MS; Yeh YT; Chien CH; Wang HS; Lin KT; Chang YY; Wu SH; Chen YS; Lu IL; Wu SY; Tsai TY; Chen WC; Hsieh HP; Chao YS; Jiaang WT
J Med Chem; 2006 Jan; 49(1):373-80. PubMed ID: 16392822
[TBL] [Abstract][Full Text] [Related]
25. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.
Connolly BA; Sanford DG; Chiluwal AK; Healey SE; Peters DE; Dimare MT; Wu W; Liu Y; Maw H; Zhou Y; Li Y; Jin Z; Sudmeier JL; Lai JH; Bachovchin WW
J Med Chem; 2008 Oct; 51(19):6005-13. PubMed ID: 18783201
[TBL] [Abstract][Full Text] [Related]
26. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
McIntosh CH; Demuth HU; Kim SJ; Pospisilik JA; Pederson RA
Int J Biochem Cell Biol; 2006; 38(5-6):860-72. PubMed ID: 16442340
[TBL] [Abstract][Full Text] [Related]
27. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
Idris I; Donnelly R
Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591
[TBL] [Abstract][Full Text] [Related]
28. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
29. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.
Pospisilik JA; Stafford SG; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2002 Sep; 51(9):2677-83. PubMed ID: 12196458
[TBL] [Abstract][Full Text] [Related]
30. Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases.
Stöckel-Maschek A; Mrestani-Klaus C; Stiebitz B; Demuth H; Neubert K
Biochim Biophys Acta; 2000 Jun; 1479(1-2):15-31. PubMed ID: 11004527
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
Wiedeman PE; Trevillyan JM
Curr Opin Investig Drugs; 2003 Apr; 4(4):412-20. PubMed ID: 12808880
[TBL] [Abstract][Full Text] [Related]
32. Development of potent and selective dipeptidyl peptidase II inhibitors.
Senten K; Van der Veken P; Bal G; De Meester I; Lambeir AM; Scharpé S; Bauvois B; Haemers A; Augustyns K
Bioorg Med Chem Lett; 2002 Oct; 12(20):2825-8. PubMed ID: 12270155
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
Mest HJ
Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820
[TBL] [Abstract][Full Text] [Related]
34. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.
Yasuda N; Nagakura T; Inoue T; Yamazaki K; Katsutani N; Takenaka O; Clark R; Matsuura F; Emori E; Yoshikawa S; Kira K; Ikuta H; Okada T; Saeki T; Asano O; Tanaka I
Eur J Pharmacol; 2006 Oct; 548(1-3):181-7. PubMed ID: 16973152
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
Brandt I; Joossens J; Chen X; Maes MB; Scharpé S; De Meester I; Lambeir AM
Biochem Pharmacol; 2005 Jul; 70(1):134-43. PubMed ID: 15907807
[TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
McIntosh CH; Demuth HU; Pospisilik JA; Pederson R
Regul Pept; 2005 Jun; 128(2):159-65. PubMed ID: 15780435
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of dipeptidyl peptidase activity by flavonol glycosides of guava (Psidium guajava L.): a key to the beneficial effects of guava in type II diabetes mellitus.
Eidenberger T; Selg M; Krennhuber K
Fitoterapia; 2013 Sep; 89():74-9. PubMed ID: 23707747
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
[TBL] [Abstract][Full Text] [Related]
39. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
40. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.
Reinhold D; Biton A; Pieper S; Lendeckel U; Faust J; Neubert K; Bank U; Täger M; Ansorge S; Brocke S
Int Immunopharmacol; 2006 Dec; 6(13-14):1935-42. PubMed ID: 17161346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
